Dermagnostix announces the official launch of the PsorX®-LabDisk. After the market entry with CE-IVD certification in 2022 and a following successful pilot customer phase, the innovative molecular test for the differential diagnosis of psoriasis and eczema was officially launched in June 2024.  The Dermagnostix system consisting of the LabDisk-Analyzer, LabDisk and the Connectivity Solution marks

Dermagnostix announces PsorX LabDisks are now CE-IVD test kits in Germany. PsorX is a first in-class molecular test to support differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from eczema, even in cases where conventional diagnostic methods have failed.

Dermagnostix proudly announces completion of ISO certification. Dermagnostix passed Stage 1 of ISO certification in May, 2022 and was recommended for Stage 2. In December we fully qualified our products for market entry and passed stage 2 to complete the certification of Dermagnostix and implementation of PsorX in a fully automated miniature laboratory for minimally

Dermagnostix announces the commercial pilot of PsorX LabDisks as CE-IVD test kits in Germany. PsorX is a first in-class molecular test for differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from all forms of eczema, even in cases where conventional diagnostic methods have failed.

Dermagnostix announces CE-IVD mark for PsorX LabDisk and LabDisk-Analyzer. CE-IVD mark for PsorX provides our customers with the knowledge and assurance that our point of need solution is developed with the highest standards for efficacy and safety. “The receipt of the CE-IVD mark is an important milestone for Dermagnostix as we move towards commercialization. It